A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Part A: Healthy Part B: Overweight or Obesity

In brief

This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.

Key facts

Study ID
NCT07160400
Run by
Innovent Biologics Technology Limited (Shanghai R&D Center)
People needed
104
Starts
2025-09-04
Expected to finish
2026-09-30
Last updated by the study team
2026-04-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.